The present disclosure relates to a nano-particle-based photonic crystal array for high sensitivity immunoassays.
Conventional microarrays have facilitated many breakthroughs in life sciences by identifying specific gene sequences or protein analytes. However, there is a need for further reduction in size to a nano scale. Such reduction in size offers significant advantages, particularly improvement in the assay speed as diffusion becomes less limiting. But the reduction in the size of an array poses problems that are related to a low signal to noise ratio and detectability of the signal. The size of the spots in a microarray is limited by optical resolution to dimensions of approximately a visible wavelength.
Photonic crystals (PC) have been applied in a variety of ways for enhanced biosensing. PC's have been assembled via colloids (H. Li, et al. J. Colloid Interface Sci. 356, 63-68 (2011) and Shen, W. Z. et al. Biosens. Bioelectron. 26, 2165-2170 (2011)) but this leads to complex structures that are not robust and ideal for disease diagnosis and proteomics. Ganesh et al. explored leaky modes in nanostructures to enhance emission from embedded quantum dots (Nat. Nanotechnol. 2, 515-520 (2007)). More recently the same group has demonstrated up to 89% enhancement in the limits of detection of cancer biomarkers with a Cy5 dye and photonic structure. The commercial BIND assay is an example of real-world application of nanostructures to provide enhanced detection, in this case without labels. In these examples however, the sensing element was attached to the surface of the photonic crystal.
There continues to be a need for assays with extremely low levels of detection which are robust.
In one embodiment is provided a nanoarray comprising: a first substrate; a second substrate deposited on said first substrate, said second substrate having a high refractive index and having at least one of a waveguide mode or a leaky mode; a superstrate disposed on the second substrate comprising a plurality of wells, said plurality of wells having a periodicity based on said waveguide mode or said leaky mode and one of an excitation wavelength or an emission wavelength for a signal to be measured.
In some embodiments, said nanoarray further comprises a nanoparticle disposed in at least one of said plurality of wells.
In some embodiments, said nanoparticle further comprises a fluorescent tag.
In some embodiments, said nanoparticle further comprises an antibody.
In some embodiments, said nanoparticle further comprises a bacteriophage.
In some embodiments, said nanoarray further comprises a bacteriophage disposed in at least one of said plurality of wells.
In some embodiments, said plurality of wells have a diameter of less than 100 nm.
In some embodiments, said plurality of wells comprise a plurality of diameters.
In some embodiments, said signal to be measured is an optical signal.
In some embodiments, said periodicity is based on said waveguide mode or said leaky mode, said excitation wavelength and said emission wavelength for a signal to be measured.
In some embodiments, said nanoarray comprises a photonic crystal.
Also provided is a method of constructing a nanoarray comprising: depositing a first substrate; depositing a second substrate having a waveguide mode or a leaky mode on said first substrate; depositing a superstrate on said second substrate; determining periodicity for a plurality of nanowells to be created in said superstrate based on said waveguide mode or said leaky mode and one of an excitation wavelength or an emission wavelength for a signal to be emitted from one of the plurality of nanowells; and creating said plurality of nanowells in said superstrate, said plurality of nanowells having said determined periodicity.
In some embodiments, the method further comprises disposing nanoparticle in each one of said nanowells.
In some embodiments a size of said nanoparticle is determined based upon a size of at least one of said plurality of nanowells.
In some embodiments said plurality of nanowells have a plurality of diameters.
In some embodiments said periodicity is determined using the equation D=λm/n2·cos (φ) wherein D=periodicity; λ is said wavelength; m is an order of diffraction; n2 is a refractive index of said second substrate and φ is an internal diffraction angle between diffracted light and a surface of the nanoarray.
In some embodiments said refractive index of said second substrate is 1.
Unless otherwise stated, the following terms used in this application, including the specification and claims, have the definitions given below. It must be noted that, as used in the specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. The practice of the present invention will employ, unless otherwise indicated, conventional methods of biology, chemistry and spectroscopy.
Any terms not directly defined herein shall be understood to have the meanings commonly associated with them as understood within the art of the invention. Certain terms are discussed herein to provide additional guidance to the practitioner in describing the compositions, devices, methods and the like of aspects of the invention, and how to make or use them. It will be appreciated that the same thing may be said in more than one way. Consequently, alternative language and synonyms may be used for any one or more of the terms discussed herein. No significance is to be placed upon whether or not a term is elaborated or discussed herein. Some synonyms or substitutable methods, materials and the like are provided. Recital of one or a few synonyms or equivalents does not exclude use of other synonyms or equivalents, unless it is explicitly stated. Use of examples, including examples of terms, is for illustrative purposes only and does not limit the scope and meaning of the aspects of the invention herein.
All references, issued patents and patent applications cited within the body of the specification and appendix are hereby incorporated by reference in their entirety, for all purposes.
Disclosed herein is a simple PC-immunoassay platform and methods for fabricating the same. The platform includes a photonic crystal coupled to a pixilated microarray. The periodicity of the wells in the photonic crystal array are designed based the leaky wave-guided modes of the high refractive index material of which the array is made. In some embodiments the periodicity of the wells is further designed using the wavelength of an electromagnetic signal to be detected. In some embodiments, the periodicity of the wells is further designed using a wavelength of electromagnetic radiation used to excite the sample resulting in a signal to be detected. In some embodiments, the periodicity of the wells is further designed using both the excitation and emission wavelengths involved in the detection of the assay. The electromagnetic signal to be detected may emanate from the analyte of interest to be measured or from a tag added to the analyte of interest. In either case that signal may result from the analyte of interest or tag with or without initial excitation with electromagnetic radiation. In some embodiments either the excitation or emission radiation, or both, are in the optical spectrum.
This design provides significant enhancements in detection. Surprisingly, using nanoparticles provides orders of magnitude improvement in limits of detection over using microparticles. The photonic crystal also serves as an electrophoretic particle entrapment system (EPES) to generate nanopixels.
Preferably the nanoparticles and thus the wells are less than 100 nm as this size allows for better exploitation of the enhanced fluorescent excitation and extraction that is afforded by coupling to the nano-photonic crystal structure with optimized periodicity. In one embodiment, the nanoparticles are polystyrene beads. Multiplexed arrays are prepared by adding particles step-wise from largest to smallest to the wells of the nanoarray.
In one embodiment, nanoparticles with antibodies attached are captured in wells on the chip. Antibodies are conjugated to the surface of nanoparticles passively or covalently. Not all antibodies attached to nanoparticles need to be the same. By tailoring the surface charge of the nanoparticles with various functional groups (e.g., carboxylic/amine groups) or by embedding super-paramagnetic particles within charged nanoparticles allows for directing nanoparticles with different antibodies to the desired location on the array. Additionally, different size nanoparticles can be used for different antibodies. In such an embodiment, an array with wells sized for each of the different antibody-nanoparticle conjugates is prepared. The multiplex array is assembled by adding the various nanoparticle-antibody conjugates from largest to smallest such that they end up in the correct-sized well.
In some embodiments, polystyrene nanoparticles that are functionalized with streptavidin are immobilized into the nanowells with the EPES method. With a bacteriophage-based analytical method, targeted pathogenic bacteria are infected by these viruses, leading the production of secondary phages. As secondary phages are flowed over the nanowells, an electrostatic potential is applied to direct the phages, with their net charge, towards the wells where binding of their biotin to the immobilized streptavidin can take place, overcoming the kinetic limitation that would be imposed by slow diffusion of the relatively massive phages.
The disclosed nanoparticle-based immunoassay achieves attomolar sensitivity with high signal to noise ratio, especially from a microspot that is pixelated with a PC structure. Particles are commonly used as solid supports for antibody immobilization to improve the control of antibody concentration, to improve the speed of assays, and to facilitate separation from solution by making use of the well-controlled surface area, surface charge, functional groups and choice of signal transduction that particles can provide. The disclosed nanoparticle-based immunoassay combines the advantages of particle-based assays and uses the particles to construct a well-ordered nanoscale array of particles in a fast, efficient manner. Negative charges on the carboxylated particles enable use of electrophoretic transport for localizing particles to nanoscale wells with an electrically conductive substrate (ITO) with positive charge at the bottom of each well. In terms of realizing a PC structure, a solid immunocomplex consisting of capture antibodies, analytes and detection antibodies plus fluorophores sitting on the high refractive index substrate (ITO) exploits the fluorescence excitation due to leaky modes created from the guided mode resonances confined in both the superstrate (PMMA) and substrate (ITO). In order to achieve a regular PC structure, reliable and consistent deposition of particles into their corresponding nanowells is used: the EPES method demonstrated 100% trapping efficiency given sufficient time (
The combination of nanoparticles in an array of nanowells, constituting in effect a pixelated single micro-spot (52 μm×52 μm), achieves extremely low limit of detection (LOD). Pixelation of a microspot down to 40 nm with specific periodicity is an important factor in coupling the Bragg scattering with resonances in a PC structure for signal extraction. For 200 nm particles in the absence of resonance, diffraction still provides an enhancement of fluorescence. (Anal. Biochem. 313, 262-266 (2003)). Diffraction effects progressively vanish with an increase in the size of the particles, according for the observed increase in the LOD (
In the detection of cancer biomarkers in serum, careful rinsing procedures reduce false-positive effects that arise from other proteins in the serum. A one-time rinsing with 10 μm-droplet of deionized water results in highly effective particle removal in the EPES. Effectiveness of the simple rinsing is verified by demonstrating negligible values of the negative control compared to background noises using only serum. Protein fouling of carboxylated polystyrene particles was prevented due to the hydrophilic hairy surface provided by carboxyl groups. (Anal. Chim. Acta 584, 252-259 (2007)) Considering that the least amount time for immobilizing protein solution to bare PMMA surface is typically over one hour, the 20 min used for incubation time in the 40 nm-PC-nanoarray was not enough time for protein fouling.
With the used of 40 nm-particles in a pixelated-nanoarray with PC structure, the LOD was improved a million fold (10 aM) over the corresponding conventional ELISA for detecting HER2 in serum. This remarkably low LOD is well beyond the limit indicated by the equilibrium dissociation constant, Kd. Microspot assays by themselves are known to reduce the LOD well below the levels associated with Kd, due to increased density of capture antibody and lower limits of detectable detection antibody. (Anal. Chim. Acta 227, 73-96 (1989)) As the signal to noise ratio of the detection system is further improved in the disclosed system with the nanophotonic effect, further gains in LOD can be realized. A simple analysis shows that Kd is not the controlling factor under a set of limiting conditions. If the total antigen concentration [Ag]<<[Ab] where [Ab] is the total available antibody concentration, then [Ab] is approximately constant. Furthermore, if [Ab]>>Kd then it is straightforward to show that the concentration of the bound complex [AgAb] is approximately independent of Kd and proportional to [Ag]. These conditions are satisfied with our assay system, and are only feasible as a result of the ultrasensitive detectability of the nanophotonic array and the small scale of the microspot.
This sensitivity is much higher than is needed for clinical application of the HER2 assay because the threshold level to determine the existence of breast cancer tumor is 15 ng/ml23. However, this model assay serves to demonstrate the significant advantages of using a particle-based immunocomplex within a PC structure that is constructed with nanoparticles in wells.
A non-optimized array used to measure 3-PBA35 demonstrated a limit of detection of 0.0064 μg/L which corresponds to 30 pM. This represents a 16-fold enhancement of sensitivity compared to a conventional assay on solid support.
The disclosed arrays can be reused if electro- or magneto-phoretic methods are used to place the nanoparticles in the wells of the array and then to remove them as well, followed by the addition of new nanoparticles to the wells.
40 nm-Fluorescent carboxylated polystyrene (PS)-nanoparticles (F-8789; ex: 660 nm em: 680 nm) were purchased from Invitrogen (Carlsbad, Calif.). 200 nm-Fluorescent carboxylated PS nanoparticles (FC02F/9770; 660/690) and 1 μm-fluorescent carboxylated PS microparticles (FC04F/8608; 660/690) were purchased from Bangs Laboratories (Fishers, Ind.). 5 μm-Fluorescent-carboxylated-PS-microparticles (2308; ex: 660/685) were purchased from Phosphorex (Fall River, Mass.).
Goat-anti-rabbit IgG and goat-anti-rabbit IgG-Alexa 532 used for capture antibody and detection antibody respectively were purchased from Invitrogen. Monoclonal capture antibody to HER2 (MAB1129), biotinylated polyclonal detection antibody to HER2 (BAF1129) and recombinant HER2 were purchased from R&D Systems, Inc. (Minneapolis, Minn.). Streptavidin-Alexa 532 was purchased from Invitrogen. TMB (3,3′,5,5′-tetramethylbenzidine) was purchased from Sigma-Aldrich (St. Louis, Mo.). Streptavidin-horseradish peroxidase (HRP) was purchased from Pierce Thermo Pierce Scientific (Rockford, Ill.).
Indium tin oxide (ITO) coated glass wafer (CG-81N-1515; resistance: 30-60Ω) was purchased from Delta Technologies (Stillwater, Minn.). All chemicals used for fabrication of the arrays/well were obtained from University of California Davis Northern California Nanotechnology Center Acetone (Sigma-Aldrich, St. Louis, Mo.), LOL-2000 (MicroChem, Newton, Mass.), 2% 950 PMMA A2 (MicroChem), 1:3 methyl isobutyl ketone (MIBK, Sigma-Aldrich), isopropyl alcohol (IPA, Mallinckrodt Baker) and CD-26 (tetramethylammonium hydroxide, MicroChem). 100×-infinity corrected objective lens (M Plan APO; NA: 0.7; working distance: 6.0 mm; focal length: 2 mm) was purchased from Mitutoyo (Kawasaki, Japan). The beam-splitter (FF545/650-D100), 532 nm-long pass filter (BLP01-532R-25), 532 nm notch filter (NF01-532U-25) and 633 nm notch filter (NF02-6335-25) were purchased from Semrock (Rochester, N.Y.). The single photon counting-avalanche photodiode (SPAD; SPCM-AQRH-13; dark count: 500 counts/s max) was purchased from PerkinElmer (Waltham, Mass.). The CCD camera (TCA-5.0C, 5.0 MP) for imaging the arrays/well with fluorescent particles was purchased from Tucsen Image Technology Inc. (FuJian, China).
A glass substrate is coated with <100 nm indium tin oxide (ITO). ITO provides optically transparent electrodes for electrophoretic manipulation of nanoparticles. The top layer is polymethyl methacrylate (PMMA)
Fabrication of Periodic Nanowell Arrays with Suitable Geometries to Generate Resonance Guided Modes in the Substrate and the Superstrate
Method 1—After determining the label to be used in the assay and its emission wavelength, a standard e-beam lithography technique prepares nanoarray chips with different periodicity and depths of the wells predetermined by finite element modeling of the determined emission wavelength of the label(s) selected for the study. Modeling ascertains the periodicity and geometry of the arrays, resulting in an enhanced excitation and emission from the label. The modeling used is described in further detail in Example 5.
Method 2—Nanoimprint lithography a simple mechanical stamping of polymer coated substrates by molds—can also be used to prepare the nanowell arrays. As in the case of the e-beam technique, a customized stamp is developed based on the computer calculations using the determined emission wavelength of the label(s). The arrays are generated by stamping the pattern on PMMA held at its glass transition temperature (˜105° C.).
Finite element software was used to design periodicity of nanowells. The model is shown in
The interaction of the light with the PC structure was modeled by employing the electromagnetic wave model in the RF module of COMSOL Multiphysics (v. 4.1; COMSOL Inc, Burlington, Mass., USA). Normal incidence of the transverse electric (TE) field of the incoming electromagnetic wave was assumed, consistent with the experimental conditions. Maxwell's equations were solved for the given frequency, electric field of the TE mode of electromagnetic wave, and the refractive index and the geometry of the PC.
The coating layer of the photoresists was assumed to be a single layer of PMMA because the difference of permittivity between the PMMA and LOL was not significant. A scattering boundary condition was adopted in the model. Based on the measured power of the 532 nm laser diode intensity focused on the PC, the boundary value of the incoming electric field was set to 6140 V/m. The electric fields at the other boundaries were set to zero. The same boundary conditions were used in all cases.
To experimentally verify the presence of resonances due to the periodic nanostructure two different refractive index-materials, glycerin (refractive index: 1.47) and water (1.33) were added to the particle-based immunocomplex contained in the array of 40 nm wells. The intensity of the fluorescence was measured after the addition of each of the fluids and was compared to the intensity observed when air was the surrounding medium. For each test, rabbit IgG was used to construct the immunocomplex on the particles under the same conditions that were used for the main experiments. The addition of water to the top of the chip caused a 1.3 times decrease in the measured fluorescence; the addition of glycerin caused a six fold reduction in fluorescence signal (Table 2). The reduction of signal with reduction in relative difference in refractive index is consistent with the presences of resonances that support enhanced fluorescence detection.
The creation of guided mode resonances with high refractive index materials is directly associated with the increased extraction of light from the structure. (OPTICS EXPRESS 16, 21626-21640 (2008) The emitted light from the fluorophores confined on top of high refractive index-material is extracted via coupling to their leaky modes, leading to amplification of the emission, as long as conditions of size and periodicity are met—as they are with the smallest particle and wells that we used. The incorporation of 40 nm particles into the wells efficiently utilizes the tail of the near-field evanescent field that extends into the superstrate region (PMMA) for excitation of the fluorophores on its surface. On the other hand, for 200 nm and 1 μm wells, mode coupling was not significant as the size of the particle imposed restrictions on the periodicity and the depth of the well: these are important parameters that contribute to the formation of the guided mode resonances. (Appl Optics 4, 1275-& (1965)) For example, the depth of the periodic structure, t, must satisfy the relation λG/2>l>λG/4 for first order diffraction, where λG is the wavelength of the light experiencing the guided mode resonances. Therefore, considering the emission wavelength of Alexa-532, the effective range of the depth is 278 nm>l>139 nm. In addition, 1 μm particles incorporated into an array showed strong Mie scattering due to the large diameter of the particle (J. Opt. Soc. Am. B 9, 1585-1592 (1992)), which prevented the guided mode resonances from being created in the high refractive index-material (ITO). The Mie scattering interferes with the Bragg scattering that drives extraction of the emitted fluorescent signal. It should be noted that the guided mode resonances condition for 1 μm particles was not achieved even by increasing the depth of the periodic structure.
1 ml of 0.05% (w/v) fluorescent carboxylated polystyrene particles (40 nm, 200 nm, 1 μm and 5 μm) were coated with goat-anti-rabbit IgG by passive adsorption considering 100%-bound coverage of the antibody to surface of the particle based on particle size. The mixing time was 2 hours at room temperature followed by overnight incubation at 4° C. The mixed solution was then washed and finally suspended in DI water. After trapping the particle-goat-anti rabbit IgG into nano- or micro-wells corresponding to their sizes, 10 μl of target rabbit IgG dissolved in 1×PBS buffer was dropped to the area where total nine arrays/wells (the distance between the arrays/wells was 250 μm) were located-hence the amounts of the target molecules in 10 μl were shared by an individual array that was the unit for signal harvesting. The arrays/wells were then incubated for 20 min at room temperature followed by removal of the solution. Finally, 10 μl of 10 μg/ml goat-anti rabbit IgG-Alexa 532 dissolved in 1×PBS buffer was dropped onto the arrays/wells. The chip was then incubated for another 20 min followed by removal of the solution. Concentrations of the target were varied from 10−9 μm/ml to 1000 μg/ml while the concentration of fluorescently labeled antibody was fixed.
The single photon counting detection system was used for excitation with a 532 nm-laser and collection of 555 nm-emitted light from the immunocomplex on the detection area of the array (52 μm×52 μm; white broken line in
The photons of light emitted from the immunocomplex were then detected by the single photon counting avalanche photodiode which generated one pulse per photon. One datum point on the curve was obtained from averaged numbers of pulses counted for 20 seconds using the oscilloscope. LODs were determined from the signal (dash line on
The 40 nm-nanoarray with 650 nm-periodicity showed the highest intensity of fluorescent signal from the array. The intensity decreased as the size of the wells increased. The 40 nm-nanoarray and 200 nm-nanoarray (periodicity: 2 μm) showed the lowest limits of detection (LOD) at 10−6 μg/ml, corresponding to 7 femtomolar concentration of the rabbit-IgG (molecular weight: 144 kDa), while the 1 μm (10 μm-periodicity)-microarray or 5 μm well showed 10−3 μg/ml and 1 μg/ml-LOD, respectively. The linear detection range was 10−6 μg/ml to 10 μg/ml (R2: 0.92 or 0.94) for 40 nm- and 200 nm-nanoarray while it was 0.1 μg/ml to 10 μg/ml (R2: 0.91) and 1 μg/ml to 10 μg/ml (non-estimated R2 value based on only two datum points in the linear range) for 1 μm and 5 μm structures, respectively, indicating that the arrays pixelated with the nanoparticles showed a significantly greater linear detection range than a single microparticle in a particle based immunoassay.
Optimization was performed for the 40 nm-nanoarray to obtain first order diffraction (m=1) that yields the biggest enhancement of guided mode resonance for excitation (532 nm) and emission (555 nm) light. The formula applied for the optimization of the periodicity of the photonic crystal was derived from
sin(θ)=(β±m2π/D)/n1k (1)
where θ is the angle of incidence of light with respect to the normal to the photonic structure surface. β is the in-plane propagation constant given by β=n2k cos(φ), m is the order of diffraction, D is the periodicity of the photonic structure, k is the wave vector given by k=2π/λ, n1 is the refractive index of the medium the light is incident, and n2 is the refractive index of the photonic structure. (OPTICS EXPRESS 16, 21626-21640 (2008) and Ieee Journal of Quantum Electronics 33, 2038-2059 (1997)) Equation (1) applies in the limit of φ→0°, where φ is the internal diffraction angle between the diffracted light and surface; this approximation serves to provide a rough guide to designing the nanostructure. Solving for θ→0 (for normal incidence);
D=λm/n
2·cos(φ) (2)
Taking an average refractive index for the photonic structure to be n2=1.6 and taking the wavelength for excitation and emission to be 532 nm and 555 nm respectively, we obtain a value for D of ˜350 nm for first order of diffraction. A numerical model based on this structure confirmed the formation of modes within this periodic structure (
Enhanced limits of detection can be of great benefit for the early diagnosis of disease and infection. An immunoassay for HER2 positive breast cancer in human serum provides a convenient model for testing the practical value of the PC/nanoparticle assay given the ready availability of both antibodies and target molecules in known concentrations. In practice, however, the natural background levels of HER2 may obviate the need for the reduction of the LOD to very low levels. A standard curve was prepared using the optimized array of 40 nm wells as well as conventional ELISA.
A 96-well ELISA plate (Maxisorp, Nunc) was coated with monoclonal capture antibody to HER2 at 8 μg/ml in PBS by 2 h incubation at 37° C. Non-specific binding sites of the plate were blocked with 400 μl of 1% BSA in PBS per each well, followed by 2 h incubation at 37° C. One hundred μl of various concentrations of HER2 diluted in PBS (25.6×10−6, 0.128×10−3, 0.00064, 0.0032, 0.016 μg/ml) were added to wells and the plate was incubated for 1 h at room temperature with gentle rocking. The plate was washed five times with PBST and 100 μl of a biotinylated polyclonal detection antibody to HER2 was added. After 1 h incubation at room temperature, the plate was washed five times with PBST and then 100 μl of streptavidin-HRP (1/6000 dilution in PBS) was added and the plate was incubated at room temperature for 1 h. The plate was washed five times with PBST and 100 μl of the HRP substrate solution (400 μl of 0.6% TMB in DMSO and 100 μl of 1% H2O2 solution into 25 ml of citrate buffer) was added and the reaction was stopped after 15 min by adding 50 μl of 2 M H2SO4 solution. Absorbance was obtained by reading the plate at 450 nm with a plate reader (Molecular device, Sunnyvale, Calif.).
For the nanoarray-created standard curve, the recombinant HER2 was spiked to 25% human serum to show the reliability in a clinical diagnosis. The mixing ratio of serum to PBS buffer was chosen to reduce matrix effects. (Nat. Biotechnol. 28, 595-599 (2010)) The concentrations were 10−9, 10−6, 10−3, 0.01, 0.1, 1, 10 μg/ml. Background noise was 13±4 photons/second. Non-specific binding of fluorescently labeled detection antibody to either the particle-monoclonal capture antibody to HER2, or to the surface of PMMA, gave rise to a signal of 12±2 photons/second (background noise excluded). To test for any false-positive effect caused by the residue of either unbound HER2 to the particle-capture antibody or fluorescently labeled detection antibody in the wells after incubation followed by removal of solution, the particles without capture antibody were used for an immunoassay on the array (other conditions were same). The signal was not different from the background noise. For a negative control, non-spiked serum in PBS was used: serum contains a number of different kinds of proteins with millimolar concentrations (Wild, D. The Immunoassay Handbook, Edn. 3rd. (Elsevier, New York, N.Y.; 2005)) that could present interferences in the assay. The signal difference between the negative control and background noise was negligible at one photon/second. The test results for non-specific binding and the negative control were in the range of the background noise within three standard deviations.
Referring to
In one embodiment, a low static voltage of 2 V is applied across the photonic crystal to immobilize T7 phages onto an array.
Water, milk and apple juice samples inoculated with a specified concentration of non-pathogenic variant of E. coli 0157-H7 (10-103 cfu/ml) will be passed through a filter membrane with immobilized phages at specified flow rates (5 ml/min to 50 ml/min).
After initial capture of bacteria on filter membranes, the filters will be incubated for 30-60 minutes to allow for infection and amplification of phages. Amplified phages will be collected onto the nanophotonic biosensor platform by the electrophoresis technique.
A photonic crystal in microarray format was used to determine the limit of detection of staphylococcal enterotoxin B (SEB) in PBS buffer (▪) and SEB in spiked milk (oval).
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to one of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the invention as defined in the appended claims.
This application claims the benefit of the earlier filing date of U.S. Provisional Application 61/584,230 filed Jan. 7, 2012 which is incorporated by reference in its entirety for all purposes.
This invention was made with government support under P42ES004699 awarded by the National Institutes of Health and 2005-35603-16280 awarded by United States Department of Agriculture. The government has certain rights in the invention.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US13/20597 | 1/7/2013 | WO | 00 |
Number | Date | Country | |
---|---|---|---|
61584230 | Jan 2012 | US |